Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals

What Was Tested

Researchers studied Bimagrumab in the context of insulin resistance, prediabetes & type 2 diabetes in this randomized controlled trial publication.

Who Took Part

According to the abstract, 16 people were involved.

PubMed tags the participants as both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Because people in this Bimagrumab study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the people nor the staff measuring them knew who was on Bimagrumab, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Bimagrumab could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Bimagrumab study would be practical.

What Was Measured

PubMed files the paper under topics including Absorptiometry, Photon, Adipose Tissue, Brown, Adiposity, Anti-Obesity Agents, Antibodies, Blocking, Antibodies, Monoclonal and Antibodies, Monoclonal, Humanized.

The authors tagged it with the keywords HbA1c, activin receptor II, bimagrumab, body composition and insulin resistance.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bimagrumab in 16 people in people with insulin resistance, prediabetes & type 2 diabetes.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Bimagrumab compound page, Insulin resistance, prediabetes & type 2 diabetes research.